Pharmacogenetics of alcohol: Treatment implications

Alcoholism: Clinical and Experimental Research

Volumn 24, Issue 9, 2000, Pages 1323-1326

  Busto, Usoa E ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALDEHYDE DEHYDROGENASE; CYTOCHROME P450; CYTOCHROME P450 2D6; DIMETHYLNITROSAMINE DEMETHYLASE; NALTREXONE; UNCLASSIFIED DRUG;

ALCOHOL ABUSE; ALCOHOL METABOLISM; ALCOHOLISM; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSFORMATION; EDITORIAL; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN INTERACTION; RACE DIFFERENCE; TREATMENT FAILURE;

EID: 0033824985     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2000.tb02099.x     Document Type: Editorial

References (28)

1. Neurogenetic adaptive mechanisms in alcoholism
2. Genetic contributions to risk of smoking initiation: Comparisons across birth cohorts and across cultures
3. Serum time course of naltrexone and 6-beta-naltrexol levels during long-term treatment in drug addicts
4. Interethnic variation of drug metabolism
5. Inhibition of cytochrome P4502D6 modifies codeine abuse liability
6. Naltrexone biotransformation and incidence of subjective side effects: A preliminary study
7. Drugs of abuse: Anatomy, pharmacology and function of reward pathways
8. Pharmacogenetics of responses to alcohol and genes that influence alcohol drinking
9. Ethanol metabolism, cirrhosis and alcoholism
10. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects
11. Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers
12. Using fuzzy logic to predict response to citalopram in alcohol dependence
13. Myths about the treatment of addiction
14. Naltrexone and coping skills therapy for alcohol dependence: A controlled study
15. A common genetic defect in nicotine metabolism decreases smoking
16. Recommended drug treatment strategies for the alcoholic patient
17. An 8-year follow-up of 450 sons of alcoholic and control subjects
18. Inhibition of cytochrome P450 2A6 (CYP2A6) decreases smoking and activation of the procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
19. Fuzzy-pharmacology: Concepts and applications
20. Naltrexone-induced alterations in human ethanol intoxication
21. Genetically deficient CYP 2D6 metabolism provides protection against oral opiate dependence
22. A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption
23. Naltrexone: Disposition, metabolism and effects after acute and chronic dosing
24. Naltrexone in the treatment of alcohol dependence
25. Metabolism and disposition of naltrexone in man after oral and intravenous administration